Loading quotes...

Forecast

The analysts' average price target is €23.62 (+118.10%). The median is €23.62 (+118.10%).

Buy
  10
Hold
  5
Sell
  1

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Novocure presents turnaround plan with profitability targets and product launches

    At the Morgan Stanley Healthcare Conference, Novocure unveiled a three-stage plan to achieve profitability and for the first time provided financial guidance, targeting adjusted EBITDA break-even by the end of 2025. The company reported 8% volume growth in its glioblastoma business, sees further upside in the US, and identifies Japan as its fourth-largest market. New product launches for pancreatic cancer (Optune Pax, CE mark in Europe) and non-small cell lung cancer are expected to drive growth; Novocure stresses it has roughly $440 million of liquidity to execute the plan. » More on de.investing.com


  • NovoCure: market launches of Optune Pax gain momentum and drive international growth

    NovoCure reported at the Wells‑Fargo conference increasing commercial momentum, particularly for Optune Pax in pancreatic cancer with about 600 prescriptions in four months and roughly 285 active patients. The company generated positive cash flow in Q2 2026 for the first time in years and is targeting a clear path to profitability alongside double‑digit revenue growth. Growth drivers also include Optune Gio for glioblastoma and expansion in Japan; risks remain reimbursement, competition from adagrasib, and a recent cybersecurity incident with limited impact. NovoCure is keeping R&D spending around $200 million and plans to hold sales and marketing costs stable, while additional approvals and guideline inclusions should support uptake. » More on de.investing.com


  • NovoCure shows revenue growth but remains cash-flow negative as it expands TTFields devices

    NovoCure’s Tumor Treating Fields devices, including Optune Gio and newly FDA-approved Optune Pax, drove revenue growth to about $655–704 million range, but the company posted a net loss (≈$136.2 million in FY2025) and negative free cash flow (−$75.7 million) as it invests in expansion. Debt and a near 0.9x debt-to-equity ratio, reliance on single-source suppliers, and expected negative free cash flow through 2027 pressure financing needs. Valuation looks more attractive than peer Omeros, but NovoCure faces execution and reimbursement risks that could limit near-term shareholder returns. » More on finance.yahoo.com


  • Novocure shares fall after TRIDENT phase‑3 study – primary endpoint missed

    The TRIDENT phase‑3 trial by Novocure did not meet its primary endpoint in newly diagnosed glioblastoma: median overall survival 17.7 vs. 17.5 months (hazard ratio 0.953; p=0.519) in 981 patients. The result prevents a potential expansion of Optune Gio use into the earlier radiochemotherapy phase, which had been seen as an important growth driver. Consequently, the stock plunged in pre‑market trading, exacerbated by a risk‑averse market environment after signals from the Fed. » More on de.investing.com


  • NovoCure CEO sells 34,273 shares for about $615,000

    Frank Leonard, CEO of NovoCure, reported an open-market sale of 34,273 common shares on June 4, 2026, for roughly $615,000. The sale reduced his direct holdings from 493,793 to 459,520 shares, representing 6.94% of his prior direct stake, and is his largest individual open-market sale to date. No indirect or derivative interests were affected; post-transaction direct holdings were valued at about $8.3 million. » More on finance.yahoo.com

Financials

In the last quarter, NovoCure had revenue of €170.74m and net profit of -€9.21m
(EUR) September 2026
YoY
Revenue 170.74m 19.84%
Gross profit 131.43m 25.93%
Net profit -9.21m 70.99%
EBITDA 1.84m 108.18%

Fundamentals

Metric Value
Market capitalization
€1.26bn
Number of shares
116.92m
52-week high/low
€19.49 - €8.92
Dividends No
Beta
1.08
P/E ratio
-11.16
PEG ratio
-0.42
P/B ratio
3.94
P/S ratio
1.91

Company profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Name
NovoCure
CEO
Frank Leonard
Headquarters Baar,
Israel
Website
Sector
Health Care
Industry
Health Care Technology
IPO
01/10/2015
Employees 1,605

Ticker symbols

Exchange Symbol
NASDAQ
NVCR
Frankfurt
038.F
Düsseldorf
038.DU
München
038.MU
🍪

Parqet  uses cookies. Learn more